Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors

被引：0
|
作者：
Pilotto, Sara [1 ]
Bria, Emilio [1 ]
机构：
[1] Univ Verona, Azienda Osped Univ Integrata, GB Rossi Acad Hosp, Med Oncol, Verona, Italy
来源：
LUNG CANCER MANAGEMENT | 2013年 / 2卷 / 02期
关键词：
D O I：
10.2217/LMT.12.57
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：89 / 92
页数：4
相关论文
共 50 条
  • [1] First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
    Nguyen, Kim-Son H.
    Neal, Joel W.
    BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 337 - 345
  • [2] Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors
    Rossi, Sabrina
    Toschi, Luca
    Finocchiaro, Giovanna
    Di Noia, Vincenzo
    Bonomi, Maria
    Cerchiaro, Eleonora
    Ceresoli, Giovanni Luca
    Beretta, Giordano Domenico
    D'Argento, Ettore
    Santoro, Armando
    CLINICAL LUNG CANCER, 2019, 20 (02) : 82 - 87
  • [3] Management of EGFR-mutant non-small-cell lung cancer patients after first-line reversible EGF receptor-tyrosine kinase inhibitors
    Manzo, Anna
    Della Corte, Carminia Maria
    Festino, Lucia
    Fasano, Morena
    Ciardiello, Fortunato
    Morgillo, Floriana
    LUNG CANCER MANAGEMENT, 2014, 3 (01) : 77 - 84
  • [4] Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors
    Dogan, Izzet
    Khanmammadov, Nijat
    Yildiz, Anil
    Ahmed, Melin Aydan
    Vatansever, Sezai
    Saip, Pinar
    Aydiner, Adnan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (07) : 1945 - 1949
  • [5] EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?
    Cansouline, Xavier
    Lipan, Beatrice
    Sizaret, Damien
    Tallet, Anne
    Vandier, Christophe
    Carmier, Delphine
    Legras, Antoine
    CANCERS, 2022, 14 (09)
  • [6] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Fukihara, Jun
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Hasegawa, Yoshinori
    ONCOLOGY, 2014, 86 (02) : 86 - 93
  • [7] Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors.
    Aydiner, Adnan
    Dogan, Izzet
    Khanmammadov, Nijat
    Saip, Pinar
    Vatansever, Sezai
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer
    Rossi, Sabrina
    Finocchiaro, Giovanna
    Di Noia, Vincenzo
    Bonomi, Maria
    Cerchiaro, Eleonora
    De Rose, Fiorenza
    Franceschini, Davide
    Navarria, Pierina
    Ceresoli, Giovanni Luca
    Beretta, Giordano Domenico
    D'Argento, Ettore
    Scorsetti, Marta
    Santoro, Armando
    Toschi, Luca
    FUTURE ONCOLOGY, 2019, 15 (33) : 3775 - 3782
  • [9] The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
    Lee, Ji Yun
    Ku, Bo Mi
    Lim, Sung Hee
    Lee, Min-Young
    Kim, Haesu
    Kim, Moonjin
    Kim, Sungmin
    Jung, Hyun Ae
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) : 903 - 909
  • [10] Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
    Aboubakar Nana, Frank
    Ocak, Sebahat
    PHARMACEUTICS, 2021, 13 (09)
12345